Interleukin 1 enhances growth factor-dependent proliferation of the clonogenic cells in acute myeloblastic leukemia and of normal human primitive hemopoietic precursors by unknown
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IL-1 is an important growth regulatory molecule secreted by stimulated macro-
phages (1) and a variety of other cell types (reviewed by Duff, reference 2). Molec-
ular cloningofthe sequencesencoding IL-1 has revealed the existenceoftwodistinct
but related species ofIL-1, designated IL-1a and IL-1R, which act through a common
receptor (3) and appear to have very similar if not identical biologic activities (4).
IL-1 was firstidentified as alymphocyte-activating factor, but morerecently hasbeen
found to possess many different activities with a wide variety ofcell types. IL-1 acts
as acofactorforCon A activation ofrestingT cells(5); as an inducerofIL-2 production
by T cell lines (6); as a growth and differentiation factor for B cells (7); and as a
primary mediator of the inflammatory response (8, 9).
The importance of IL-1 in the regulation ofhemopoiesis has only recently been
widely recognized. Many different investigators have shown that IL-1 induces the
production ofseveral different hemopoietic growth factors, including both granulo-
cyte/macrophage CSF (GM-CSF)' and granulocyte CSF (G-CSF) by a variety of
cell types including lung fibroblasts (10), human mononuclear phagocytes (11), and
bone marrow-derived stromal cells (12). In addition, IL-1 has been found to share
many of the activities originally ascribed to the cytokine known as hemopoietin 1
(H-1) (13-16). Thus, IL-1 acts synergistically with both macrophage CSF (M-CSF,
also known as CSF1) andG-CSF in the stimulation ofmurine macrophage progen-
itors having high proliferative potential (16, 17) and with GM-CSF in the stimula-
tion ofproliferation ofprimitivemurine stem cells(15). Finally, incubation ofhuman
bone marrow cells with IL-1 results in an increased proportion ofhemopoietic stem
cells in cycle (18).
We havepreviously described a growth factor activity called leukemic blast growth
factor (LBGF) (19, 20) that supports colony formation by leukemic blast progen-
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itors, found in the peripheral blood of patients with acute myeloblastic leukemia .
One of the best sources of this activity is the conditioned medium (CM) from a
human bladder carcinoma cell line designated HTB9-5637 (19) . This cell line has
been shown to produce G-CSF (21), GM-CSF (22), and, most recently, IL-1a (15) .
Analysis of the HTB9-CM has previously demonstrated that both GM-CSF and
G-CSF contribute to the LBGF activity elaborated by the carcinoma cells . Here,
we report that IL-la also acts synergistically with GM-CSF and to a lesser degree
with G-CSF in supporting acute myeloblastic leukemia (AML) blast cell colony for-
mation . Reconstitution experiments with all three cytokines suggest that the combi-
nation of factors can account for all of theHTB9-CM LBGF activity . Furthermore,
when tested with normal bone marrow-derived human progenitors, IL-la also acted
synergistically with GM-CSF in the stimulation of colony formation by primitive
GM-CFC, erythroid (BFU-E), and multipotential (CFU-GEM) progenitors . These
studies indicate that IL-la functions in thehuman system, as has been demonstrated
previously in the murine system (15), as a regulator of early stem cell proliferation .
Source of Cells and Growth Factors.
Materials and Methods
Blasts were separated from the peripheral blood ofAML patients at presentation (Hotel-
Dieu Hospital, Montreal, Canada) by centrifugation on a Ficoll Hypaque gradient (Phar-
macia Fine Chemicals, Laval, Quebec, Canada) . Cells were stored at -70°C or in liquid
nitrogen until use . Normal bone marrows came from marrow aspirates done for diagnosis,
which subsequently appeared to have a normal cellularity and normal differential cell count .
IL-1 a (Genzyme, Boston, MA), purified from Escherichia coli extracts to a final specific ac-
tivity of 10s U/mg, was stored in aliquots at 4°C . GM-CSF was purified to a specific ac-
tivity of 8 x 10 6 U/mg, from culture supernatants of aCHO cell line transformed with the
human GM-CSFcDNA (23) . rG-CSF was the crude conditioned medium from anotherCHO
cell line engineered to express human G-CSF . 1 U/ml of activity corresponds to a concentra-
tion resulting in half maximal stimulation proliferation of primary CML blasts . The anti-
body toGM-CSF was a polyclonal rabbit antiserum raised against rhGM-CSF. At a dilution
of 1 :500, it neutralized 50 U/ml of GM-CSF.
HTB9-conditioned medium was harvested 1 wk after confluency, filtered, and stored at
4°C as described elsewhere (19) . It had an optimal activity at 10% (vol/vol) in culture and
was included in all experiments as a positive control .
Assays of Growth Factors.
Blast Assay.
￿
AML blasts were plated at concentrations chosen so that no colony growth
occurred in absence of an exogenous source of growth factor (7,000 cells per 100 gl for all
five patients included in the study) . Cells were plated in Iscove's modified Dulbecco'smedium
(IMDM, Gibco, Grand Island, NY), supplemented with FCS (10%, Gibco), and viscosified
with methylcellulose (1% wt/vol, Fluka, Switzerland) . The cultures were done in quadruplates
in 96-well dishes (Linbro, Flow Laboratories, McLean, VA) at 100 41 per well .
NormalBone Marrow Cultures.
￿
Mononuclear cells were separated on a FicollHypaque gra-
dient, depleted of adherent cells by an overnight incubation in IMDM supplemented with
FCS (10%) . Nonadherent cells were plated at 4 x 104 cells/ml in IMDM supplemented with
FCS (10%), deionised and delipidated BSA (10 mg/ml, electrophoretically pure, Hoechst,
Behring Diagnostics, La Jolla, CA), iron saturated transferrin (300 wg/ml, Hoechst), and
a-thioglycerol (7.5 x 10-5 M, Sigma Chemical Co., St . Louis, MO) and viscosified with
methyl-cellulose (1%, Fluka), as described previously (24) . Step 1 eythropoietin (Terry Fox
Cancer research laboratories, University of British Columbia, BC) was added at a final con-
centration of 1 U/ml . Cultures were done in duplicate, in 35-mm Petri dishes (Lux, Miles
Scientific, Napierville, Quebec, Canada) at 1 ml per dish . Colonies were enumerated 14 dHOANG ET AL.
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afterinitiating the cultures and were scored as erythroid (BFU-E), granulocytic and macro-
phagic (GM-CFC), or granulocytic/erythroid/macrophagic (CFU-GEM), based on colony
morphology.
Northern Blots and Hybridisation Conditions.
￿
RNA was extracted from the HTB9 cells by
the guanidine isothiocyanate technique (25), denatured in the presence of glyoxal (BDH,
Toronto, Ontario, Canada) subjected to electrophoresis in 1% agarose (Pharmacies Fine Chem-
icals, Uppsala, Sweden), and transferred to nitrocellulose as described by Thomas (26). The
IL-la probe was the Pstl fragment of the human IL-la cDNA (3). It was labeled by random
priming with the Klenow to a sp act of 2 x 108 cpm/wg (27). The filter was prehybridized
for 4 h at 65oC in presence of 120 mM Tris/8 mM EDTA/600 mM NaCl pH, 7.4, (4 x SET),
0.1o1o sodium pyrophosphate, 0.2% SDS (BioRad, Richmond, CA), and Heparin (100 ug/ml,
Sigma Chemical Co.) . The filter was hybridized overnight in the same buffers as aboveexcept
that the heparin was increased to 500 wg/ml, dextran sulphate (Pharmacies Fine Chemicals)
added at 1 g/9.6 ml and the probe added at 106 cpm/ml. The filter was washed under strin-
gent conditions (final wash at 0.1 x SET, 0.2 % SDS for 30 min at 65oC) and exposed. The
relative mobilities of molecular weight standards were obtained using 12P-labeled denatured
fragments of phage X DNA (Hind III) and tp 7( (Hae III), which were analyzed in parallel.
Results
Blasts from five patients with AML (Table 1) were plated in the presence of in-
creasing concentrations of rIL-la either alone or in the presence ofan optimal con-
centration of rGM-CSF, determined by a separate titration (Fig. 1 A). IL-1a had
no effect by itself (Fig. 1 B) but synergized with rGM-CSF in the stimulation of
blast colonies in threeout offive AML samples. The effect was striking, with a 6-10-
fold increase in colony count over that induced by rGM-CSF alone at the highest
concentration of rIL-1a (Fig. 1 C) . No effect, neither additive nor inhibitory, was
seen with AML-4 (Fig. 1) and -5 (Fig. 4).
While GM-CSF showed little stimulation ofblast colonies by itself, rG-CSF under
the same culture conditions appeared to be a more potent stimulator (Fig. 2 B).
For that reason, the synergistic effect of IL-1a with G-CSF was less dramatic than
that observed with rGM-CSF It was, however, significant with AML-1 and -3 and,
to a lesser degree, with AML-4 (Fig. 2 A). No effect was observed with AML-2 and -5.
Previous studies have indicated that GM-CSF and G-CSF have a synergistic effect
on AML blast progenitors (28, 29). The combination of the two growth factors, how-
ever, does not reach the level of stimulation observed with HTB9 CM (Fig. 3, or-
dinate). We therefore tested whether or not IL-la would exhibit a further synergistic
TABLE I
Clinical Data on the AML Patients Included in the Study
The proportion of blasts was expressed as a percentage of total nucleated cells
in the peripheral blood.
Patient FAB classification Percent blasts
AML-1 M2 68
AML-2 M4 60
AML-3 M56 38
AML-4 M4 >95
AML-5 M3 90
AML-6 Ml 40466
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activity in the presence of the two CSFs. The dose-response curves shown in Fig.
3 indicated that 10-15 U/ml IL-1 reconstituted the level ofstimulation observed with
HTB9 CM in the presence of both rGM-CSF and rG-CSF. Because the cell line
HTB9 produced IL-la (Fig. 5) and both GM-CSF and G-CSF (21, 22), the syner-
gistic effects of the three growth factors could account for most of the stimulatory
activity observed in the medium conditioned by the cells. No additional effect of
IL-1a was seen with AML-5, whereby the synergistic effects of GM-CSF and G-CSF
reconstituted the stimulation induced by HTB9-CM indicatingthat these cellswere
not responsive to IL-la (Fig. 4). The same growth pattern was observed with AML-
6 (Fig. 4). There was however a discrepancy with the other AML blasts in that rIL-
la alone was capable of supporting colony formation up to 22% of that obtained
with our standard HTB9-CM.
rIL-la " rG-CSF (ISU/ml)
￿
B
￿
rG-CSF
rIL-la CONCENTRATION (units/ml)
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rG-CSF CONCENTRATION (units/m1)
FIGURE 1.
￿
Effects of rIL-la on the proliferation of blast
clonogenic cells in the presence of rGM-CSF. (A and
B) Individual titration curves for rGM-CSF and rIL-
la. (C) Titration ofrIL-la in the presence of rGM-CSF
(50 U/ml). Values shown were normalized tothe number
ofcolonies obtained with HTB9CM. Maximum colony
counts were: 87 ± 18 (AML-1); 185 ± 23 (AML-2);
123 ± 11 (AML-3); 52 t 7 (AML-4). Error bars shown
are SD from quadruplate cultures normalized in the
same way as colony counts.
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GM-CSFhas been reported to actasan autocrine stimulatorofAMLblastprolifer-
ation (30). Because IL-la showed a synergistic activity with an exogenous source
ofGM-CSF, wetested the possibility thatit might also synergize with theautocrine
GM-CSF. Blasts from AML-6 were therefore plated at higher cell concentration
(104 per well) in order to increase the chance ofcell interaction. Datashown in Table
II indicated again that rIL-1a supported colony formation in absence of any other
growth factor and the effect was dose dependent. However, when the same titration
with rIL-1 was done in parallel in presence of the neutralizing antibody directed
against GM-CSF, no significant colony formationwasobserved. The inhibition was
too
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Absenceofsynergy between rIL-la
and rGM-CSF or G-CSF in the stimulation of
two patient samples. (Leftpanels)Individual titra
tion curves foreach growth factor alone. (Right
panels) Titration of rIL-la in the presence of
rGM-CSF (50U/ml)and/or G-CSF (15 U/ml).
Values shownwere normalized to thenumber of
colonies obtained with HTB9-CM. Maximum
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AML 4
FIGURE 3.
￿
Synergistic effects ofrIL-1a on the pro-
liferation ofblastprogenitors in thepresence ofboth
rGM-CSF and rG-CSF. Values shown on the or-
dinate were obtained with both rGM-CSF(50U/ml)
and rG-CSF (15 U/ml) in the absence of rIL-la.
Normalization and maximum colony counts as in
Fig. 1.468
￿
INTERLEUKIN 1 ON HUMAN LEUKEMIC CELLS
FIGURE 5 .
￿
The HTB9 cells express the IL-la mRNA. Total RNA
(10 pg) fromHTB9 cells was analyzed byRNA blotting using the la-
beled IL-la cDNA as probe (lane b). Total RNA from AML blasts
(lane a) were denatured and analyzed in parallel as negative control .
not due to a nonspecific toxicity of the antibody, because it did not affect colony
formation supportedby rIL-3 (Table III) . The results indicated that the stimulatory
effect observed with IL-1a alone at higher cell concentration was due to a syner-
gistic activity ofthe growth factor with theendogenousGM-CSF produced by the cells .
IL-3 has been shown to support blast colony formation (31) . We therefore tested
the possibility whether IL-1a may also enhance the IL-3-dependent colony forma-
tion fromAML blasts . Data shown in Fig . 6 indicated that addition of IL-1a to op-
timal concentrations of IL-3 resulted in a twofold increase in colony formation . En-
hancement of colony growth was dependent on the concentration of IL-la added
and was optimal at 8 U/ml .
TABLE II
Synergistic Effects of rIL-1 with the Autocrine GM-CSF Produced by AML Blasts
Blasts were from AML-6 . The polyclonal anti-GM-CSF was added at a dilution of 1 :500,
sufficient to neutralize 50 U ofGM-CSF . Results shown are mean of quadruplate cultures .
rIL-la
(U/-O
Colonies per 104 cells
- Anti-GM-CSF + Anti-GM-CSF
0 6 t 5 -
0.15 5±4 1 t 1
1 .5 9 ± 1 3 t 2
5 17 1 6 4 t 3
15 3519 4t 3i
I
v
0
U
100
50
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TABLE III
Specificity of the Neutralizing Antibody against GM-CSF
Growth factor concentrations were 10 U/ml. Erythropoietin was added to the cultures at 1
U/ml. The concentration of anti-GM-CSF was the same as in Table II. Duplicate cultures
were established with nonadherent mononuclear cells from normal donors as described in Materi-
als and Methods.
When tested on nonadherent normal bone marrow cells, rIL-la supported
erythroid colony formation (BFU-E) in theabsence ofany other growth factor (Fig.
7). No other type of colony was observed. Because IL-1 has been shown to induce
GM-CSF release from monocytes, we investigated the possibility that the stimula-
tion of BFU-E might be due to a low level of GM-CSF production by monocytes
that either were generated during the course of the culture or were not totally re-
moved by the overnight adherence. In the presence of the polyclonal antibody to
GM-CSF, the number oferythroid colonies induced by rIL-1a was reduced by half.
The results suggest that part of the effect of IL-1a on normal bone marrow cells could
be explained by an endogenous release of GM-CSF.
At low concentrations of nonadherent normal bone marrow cells, rIL-1 syner-
gized with rGM-CSF in the stimulation of multipotential colonies (Fig. 8). While
there was a sixfold increase in multipotential colonies, the increases in granulocyte/
macrophage and erythroid colony formation were only two fold (Table IV). In the
presence of rG-CSF, there was no significant effect of rIL-1 in the stimulation of
either CFU-GEM, BFU-E, or GM-CFC over the level attained with rG-CSF alone
(Table IV).
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FIGURE 6. IL-la acts synergisti-
cally with IL-3 in the stimulation
of AML blast clonogenic cells.
Blasts from AML-3 were plated at
5,000 cells per well. Maximum
colony count was 113 f 18.
Growth
Factor Antibody CFU-E
Colonies
GM-CFC
per 105
M-CFC
bone marrow cells
BFU-E CFU-GEMM
None - 660 f 120 2 1 2 4 1 2 44 1 0 0
rGM-CSF - 560 1 120 20 1 8 28 1 6 130 1 6 20 ± 2
rGM-CSF Anti-GM-CSF 504 93 0 0 64 1 30 0
rIL-3 - 558 f 9 46 1 2 24 1 2 270 1 40 36 1 4
HL-3 Anti-GM-CSF 540 1 6 88 1 2 14 1 2 270 1 14 32 1 2470
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rIL-1a CONC. (Units/ml)
FIGURE 7.
￿
Inhibition of rIL-la-supported BFU-E
colony formation by anti-GM-CSFserum. Thepoly-
clonal antibody to GM-CSF was added at afinal di-
lution of 1:1,000, sufficient to neutralize 25 U ofGM-
CSF per ml (data not shown). Culture conditions
as in Table IV.
Discussion
IL-1, long recognized as an important immune mediator, has also proved to be
capable of affecting hemopoietic progenitor cell proliferation through at least two
different mechanisms. First, IL-1 has been shownby many investigators to indirectly
support hemopoietic colony formation by activating different cell types to release
a varietyof growth factorsincludingGM-CSF and G-CSF (10-12). Second, although
IL-1 by itself is incapable of supporting hemopoietic colony formation, in the mu-
rine system it has been found to greatly enhance the abilities of the different CSFs
to support colony formation by primitive pluripotent stem cells (13-16). This syner-
gistic activity, originally associated with a cytokine designated H-1, is believed to
arise from the interaction of IL-1 with quiescent progenitors, which causes them
to enter the cell cycle and become CSF responsive (13-16). In our cultures of AML
blasts and of normal human bone marrow progenitors, we have observed similar
effects providing evidence that IL-1 functions analogously in the human system.
We have found previously that the conditioned medium from the humanbladder
carcinoma cell line (HTB9-5637) provided a good source of growth factor activity
forcolony formation by primaryAML blast cells, an activity designated LBGF (19).
In our efforts to identify the factor(s)responsible forthis activity, we have both tested
the responsiveness of AML blasts to different known growth factors and purified
the activity from the cell line-conditioned medium (HTB9-CM). This conditioned
medium has proved to be an excellent source of G-CSF (21), GM-CSF (22), and
IL-la(15). The synergistic effects of G-CSF and GM-CSF in the stimulation of AML
blast progenitorshave been well documented (18, 19); our observations here suggest
rIL"la "
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rIL-1.-
rG-CSF
la o4 r
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FIGURE 8.
￿
Augmentation of rGM-GSFdependent mul-
tipotential (CFU-GEM)colony formationofnormal marrow
precursors by rIL-la. rGM-CSF was added at a concen-
trationof 50 U/ml and rG-CSF at 15 U/ml. Values shown
on the ordinate were obtained with each growth factor in
the absence of IL-la. Culture conditions as in Table IV.HOANG ET AL.
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TABLE IV
Effects of rGM-CSF and rG-CSF on the Proliferation of GM-CFC and
BFU-Efrom Normal Donors
Results shown were the highest on a dose-response curve for each growth factor
(rGM-CSF, 50 U/ml ; rG-CSF, 15 U/ml; HL-la, S U/ml). Duplicate cultures
were established at 4 x 104 nonadherent mononuclear cells per ml.
that IL-la may alsocontribute to the LBGF activity ofHTB9-CM. In fact, the com-
bination ofG-CSF, GM-CSF, and IL-1a supports AML blast colony formation as
effectively asdoes theHTB9-CM. Further experimentswith appropriate antibodies
are underway to determine if these three factors together account for all ofthe ac-
tivity originally called LBGF.
The analysis ofthe ability of the blast cells from five different AML patients to
form colonies revealed a significant heterogeneity ofresponsiveness to the different
growth factors. IL-1a by itself was incapable of supporting blast colony formation
in cultures ofprimary blast cells plated at low density. However, with four out of
five patient samples tested, IL-1a acted synergistically with the CSFs in support of
AML blast colony formation. These five AML blast samples each had a distinct
pattern ofgrowth factor responsiveness: one sample (AML-1) yielded asmall number
ofcolonies when plated witheither G- orGM-CSF, and the colony countwasamplified
2-5-fold by addition of IL-1a; one sample (AML-2), which revealed strong synergy
in responsivenessto the combination ofGM-CSF and IL-1a, plated with comparable
efficiency in the presence ofG-CSF alone and this efficiency was not increased by
IL-1 stimulation; athird patientsample (AML-3) wasresponsive toG- but notGM-
CSF, and the plating efficiency with either CSF was significantly increased by IL-
la; the fourth sample (AML-4) was refractory to GM-CSF even in combination
with IL-1a and to G-CSF alone but revealed significant colony formation with
G-CSF in combination with IL-1a; and the fifth sample (AML-5), which displayed
no IL-la-responsiveness, yielded colonies in the presence ofeither G- or GM-CSF
alone and gave optimal colony formation with the combination of the two CSFs.
Although in these studies wehave not distinguished between direct and indirect effects
of IL-la, the observed synergy with GM-CSF and G-CSF is not likely to be due
to enhanced production ofthese factors in culture, because the synergistic effects
were clear even when the CSFs were added at concentrations at least threefold in
excess ofthose required for maximal colony formation in the absence ofIL-1a. We
have not, however, eliminated the possibility that IL-la induced the production of
othergrowth factors(IL-3 orIL-6, for example) inculture that resulted in enhanced
colony formation. In at least one case, this possibility is not likely because the GM-
CSFautocrine blasts from patient AML-6alsodemonstrated synergy when cultured
Growth factor added
Colonies per 4 x
GM-CFC
104 cells
BFU-E
None 0 6 +_ 4
rIL-1a 2 ± 0 30 1 2
rGM-CSF 22 t 1 36 t 6
rGM-CSF + rIL-la 47 f S 67 f 1
rG-CSF 50 ± 2 32 t 1
rG-CSF + rIL-la 44 f 1 35 ± 14'72
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in the presence of IL-la alone, and this colony formation was substantially blocked
by a neutralizing antibody against GM-CSF.
Our observations of the synergy between the different factors in support of the
growth ofAML blasts prompted us to test for similar effects on the colony formation
of normal human hemopoietic progenitors. When tested with nonadherent bone
marrow cells, IL-la alone was found to support the formation of a few erythroid
(BFU-E) colonies, although occasional granulocyte and macrophage colonies were
also observed (data not shown). Inclusion of a neutralizing antiserum against GM-
CSF in these cultures resulted in a 50% reduction in the colony counts, indicating
that at least part of the IL-la-supported colony formation was mediated by enhanced
production of GM-CSF by cells in the cultures. However, in the presence of exoge-
nous rGM-CSF, IL-1a resulted in a sixfold increase in the number of multipoten-
tial (CFU-GEM) colonies when compared with cultures maintained in GM-CSF
alone. A smaller enhancement of BFU-E and GM-CFC colony formation was also
observed. Although we again have not distinguished between direct and indirect
effects of IL-la, the selective stimulation of multipotential precursors is consistent
with results from studies in the murine system, which suggest that IL-1 acts syner-
gistically with various CSFs in supporting colony formation by increasingthe propor-
tion of stem cells in cycle (13-16). Nonetheless, it will be important to test IL-1 in
combination with all of the different CSFs using more highly purified human pro-
genitor cells and appropriate antisera to directly distinguish between direct and in-
direct effects of IL-1.
Analysis of normal hemopoietic progenitor populations is greatly complicated by
the extreme heterogeneity of the cells within any purified cell fraction. Although
the clonogenic cells present in circulation in any AML patient are also likely to be
biologically heterogeneous, surface antigen phenotypic analysis indicates that they
may be much less so than normal cells: roughly one third of patients have clonogenic
blast cells with surface markers characteristic of the CFU-GEM or earlier, and the
remaining two thirds appear to be related to the later, committed progenitors desig-
nated CFU-GM (reviewed in reference 32). Although the clonogenic blast cells of
AML possess growth characteristics that clearly distinguish them from their normal
counterparts, the availability oflarge numbers ofgrowth factor-responsive cellsfrom
different patients provides a unique opportunity for detailed analysis of the interac-
tions of hemopoietic cells with the CSFs and IL-1. With these cell populations, it
should be possible to determine if IL-1 stimulation ofhuman cells results in enhanced
proliferation through activation ofCSF receptor expression (14), through shortening
of the Go time of the quiescent cells (18), or through a combination of both mecha-
nisms. It will similarly be of interest to use this model to study the mechanism of
synergy between GM-CSF and G-CSF with a leukemic cell population whose normal
counterpart has yet to be described.
Summary
IL-1 is released by activated monocytes and is thought to be a key mediator of
the host immune response. The availability ofthe purified and, more recently, recom-
binant IL-1 has allowed the characterization of other biological properties of this
molecule. Thus, IL-1 is thought to have the same properties as hemopoietin 1, a
growth factor that has been shown to act on primitive murine hemopoietic cells.HOANG ET AL.
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Here we report that rIL-1 acts synergistically with granulocyte/macrophage CSF
(GM-CSF) or granulocyte CSF in the stimulation of clonogenic cells from many
patients with acute myeloblastic leukemia (AML). Although IL-1 by itself has no
effect on AML blasts, it can support colony formation under conditions where there
is detectable production of endogenous GM-CSF. IL-1 also promotes the growth
of multipotential progenitors from normal human bone marrow cells in the pres-
ence of GM-CSF. These observations support the hypothesis that in the hemopoietic
system, IL-1 has a selective effect on primitive precursors.
Receivedfor publication 8 February 1988 and in revisedform 28 March 1988.
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